{
    "lc": {
        "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {
            "story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds",
            "user_code": "GOLD_1",
            "age_group": "21_30",
            "agreed": true,
            "close_date_time": "2021-10-15 10:56:44",
            "close_timestamp": 1636973804011,
            "created": "15/11/2021 10:56:46",
            "department": "Computing",
            "disability": false,
            "ease": 5,
            "environment": "production",
            "experiment_date_datepicker": "2021-11-15",
            "gender": "female",
            "id": "d5c7c0e4-9f4a-4e76-ba04-b073eff247dc",
            "open_date_time": "2021-10-15 10:47:42",
            "open_timestamp": 1636973262564,
            "story_date": "2020-04-21 00:00:00",
            "story_source": "tpl",
            "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds",
            "summary": "An Australian study shows that Ivermectin can kill the COVID virus in 48 hours. It is a widely available drug, already approved and in use in the US. It's not sure how it works killing the COVID virus, but it's thought that it doesn't damp down that much the body cells, allowing them to clear the virus. More information will be available after the next pre-clinical studies. ",
            "task_condition": "text",
            "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds",
            "task_level": "post_graduate_phd",
            "time_taken_in_seconds": 541447,
            "what": "a new study showing the potential of Ivermectin to kill the COVID virus",
            "when_happened": "few_years_ago",
            "where_location": "Australia",
            "who": "Peter Doherty Institute of Infection and Immunity, Australia's Monash Biomedicine Discovery Institute",
            "why": "a way to slow the COVID pandemic until the vaccine will be widely available "
        },
        "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {
            "story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa",
            "user_code": "GOLD_1",
            "age_group": "21_30",
            "agreed": true,
            "close_date_time": "2021-10-15 10:35:5",
            "close_timestamp": 1636972505043,
            "created": "15/11/2021 10:35:06",
            "department": "Computing",
            "disability": false,
            "ease": 2,
            "environment": "production",
            "experiment_date_datepicker": "2021-11-15",
            "gender": "female",
            "id": "ca454aa4-9767-4b50-aa2e-c577eff70ee8",
            "open_date_time": "2021-10-15 10:29:39",
            "open_timestamp": 1636972179110,
            "story_date": "2021-06-23 00:00:00",
            "story_source": "tpl",
            "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA",
            "summary": "Novavax's vaccine might not gave a good efficacy when it comes to other COVID strains (such as the Beta strain). ",
            "task_condition": "viz",
            "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa",
            "task_level": "post_graduate_phd",
            "time_taken_in_seconds": 325933,
            "what": "results on the Novavax vaccine, related to different COVID strains.",
            "when_happened": "current_month",
            "where_location": "The US",
            "who": "Novavax staff",
            "why": "talks about a new vaccine called Novavax and the results from its trails"
        },
        "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {
            "story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19",
            "user_code": "GOLD_1",
            "age_group": "21_30",
            "agreed": true,
            "close_date_time": "2021-10-15 10:29:21",
            "close_timestamp": 1636972161097,
            "created": "15/11/2021 10:29:23",
            "department": "Computing",
            "disability": false,
            "ease": 3,
            "environment": "production",
            "experiment_date_datepicker": "2021-11-15",
            "gender": "female",
            "id": "b9b178c6-b28f-409d-93d8-21a37acd027d",
            "open_date_time": "2021-10-15 10:22:5",
            "open_timestamp": 1636971725851,
            "story_date": "2020-08-20 00:00:00",
            "story_source": "tpl",
            "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19",
            "summary": "Australian's GPs are prescribing patients with COVID a new medicine called Ivermectin as it seems to improve the symptoms . They are waiting on the vaccines, hence a medicine could help with the virus spread. ",
            "task_condition": "viz",
            "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19",
            "task_level": "post_graduate_phd",
            "time_taken_in_seconds": 435246,
            "what": "ivermectin prescribtion for COVID patients ",
            "when_happened": "current_month",
            "where_location": "Australia",
            "who": "Australian's GPs,",
            "why": "a way to overcome COVID pandemic"
        },
        "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {
            "story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve",
            "user_code": "GOLD_1",
            "age_group": "21_30",
            "agreed": true,
            "close_date_time": "2021-10-15 10:47:37",
            "close_timestamp": 1636973257267,
            "created": "15/11/2021 10:47:39",
            "department": "Computing",
            "disability": false,
            "ease": 4,
            "environment": "production",
            "experiment_date_datepicker": "2021-11-15",
            "gender": "female",
            "id": "c82b4309-4419-4bad-991d-24017869d6b9",
            "open_date_time": "2021-10-15 10:35:22",
            "open_timestamp": 1636972522689,
            "story_date": "2020-07-21 00:00:00",
            "story_source": "tpl",
            "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve",
            "summary": "Japan is the first to approve the use of a new drug called Ronapreve against COVID for high-risk, non-hospitalized patients. It is approved for emergency used in other places, such as in Europe, India or the US.  ",
            "task_condition": "text",
            "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve",
            "task_level": "post_graduate_phd",
            "time_taken_in_seconds": 734578,
            "what": "approving a drug for COVID-19",
            "when_happened": "few_years_ago",
            "where_location": "at the beginning in Japan, after that it takes place around the world, in Europe, India and the US.",
            "who": "Swiss pharma Roche, Japan's MHLW, Japanese drugmaker Chugai Pharmaceutical, ",
            "why": "explains an advance in handling the COVID pandemic via a new drug. "
        }
    },
    "tb": {
        "pfizer": {
            "story_term": "pfizer",
            "user_code": "GOLD_1",
            "age_group": "21_30",
            "agreed": true,
            "close_date_time": "2021-10-15 11:41:18",
            "close_timestamp": 1636976478389,
            "created": "15/11/2021 11:41:20",
            "department": "Computing",
            "disability": false,
            "ease": 5,
            "environment": "production",
            "experiment_date_datepicker": "2021-11-15",
            "gender": "female",
            "id": "afc2aaa6-bfa5-4c5e-8a39-0385a50a10d7",
            "open_date_time": "2021-10-15 11:20:21",
            "open_timestamp": 1636975221954,
            "summary": "Pfizer's Corona virus vaccine has been rolled out across the world, showing good results in stopping the COVID virus spread. \r\n\r\nIt was initially approved for use for adults, however as more studies are finalised, they show good results for adolescents and children. The vaccine has been approved for these age groups in spring 2021. \r\n\r\nAnother good news about Pfizer's vaccine is that it is also effective for the B.1.617.2 variant, with a efficacy of 88%. The vaccine's shelf life has been also extended from 5 to 31 days at normal fridge temperature. \r\n\r\nThese made the company very successful, recording $3.5 billion from the COVID-19 vaccine sells in the first quarter of 2021, predicting to reach $24.8 billion by the end of 2021.",
            "task_condition": "text",
            "task_key": "pfizer",
            "task_level": "post_graduate_phd",
            "time_taken_in_seconds": 1256435
        },
        "astrazeneca": {
            "story_term": "astrazeneca",
            "user_code": "GOLD_1",
            "age_group": "21_30",
            "agreed": true,
            "close_date_time": "2021-10-15 11:20:14",
            "close_timestamp": 1636975214535,
            "created": "15/11/2021 11:20:17",
            "department": "Computing",
            "disability": false,
            "ease": 4,
            "environment": "production",
            "experiment_date_datepicker": "2021-11-15",
            "gender": "female",
            "id": "0c60d257-5929-408b-b83f-f29807a292eb",
            "open_date_time": "2021-10-15 10:57:7",
            "open_timestamp": 1636973827402,
            "summary": "Astra-Zeneca vaccine against COVID-19 started to be rolled out in Europe and the US. After delays in receiving the vaccines, EU sued the company as they didn't respect the contractual agreements. The Astra-Zeneca vaccine was also shipped to other low and middle-income countries via the COVAX program. \r\nAfter 25 million people got the vaccine, a small proportion reported serious side effects such as blood cloths. Because of this, Countries around the world started to take action and limited the Astra-Zeneca vaccine roll out to only certain age groups. ",
            "task_condition": "viz",
            "task_key": "astrazeneca",
            "task_level": "post_graduate_phd",
            "time_taken_in_seconds": 1387133
        }
    }
}